KONEXBiotech & Pharma200580

Medyssey

₩12,430 0.00%2026-11-18 close
Market Cap
₩46.3B
Turnover
₩0
Volume
0 shares
Shares out.
3.7M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

A spinal implant maker with half its sales abroad

Medyssey grew 2025 consolidated revenue to KRW 28.309 billion and operating profit to KRW 3.953 billion, but overseas subsidiary restructuring and thin KONEX trading remain open issues.

  1. 1

    2025 consolidated revenue reached KRW 28.309 billion and operating profit KRW 3.953 billion, above the 2024 level of KRW 25.5 billion revenue and KRW 3.2 billion operating profit.

  2. 2

    On a 2025 basis, exports account for 60.93% of orthopedic implant sales, and overseas sales make up roughly half of the total.

  3. 3

    Reimbursed products make up about 80% of domestic sales, so demand is tied to the insurance reimbursement system.

  4. 4

    The Chinese subsidiary was suspended and closed and the Brazilian subsidiary moved into liquidation, marking an ongoing overseas restructuring.

  5. 5

    While still listed on KONEX, the stock has low trading value and a small foreign ownership stake, which limits liquidity.

02

Business structure

Medyssey, founded in 2003, manufactures spinal implants for orthopedic and neurosurgical use. Dong-Wha Pharm acquired a controlling stake in 2020, and it remains the largest shareholder with 59.95%.

The core product line is thoracolumbar spinal implants, which according to past press reports accounted for more than 90% of total sales. Patient-specific implants based on 3D printing have been added, and sales in this segment reached KRW 760 million in 2024, up 29% from the prior year.

The company is also extending into trauma fixation implants and surgical consumables such as hemostats and bone substitutes. A company official said reimbursed products generate roughly 80% of domestic sales.

Overseas, past reports describe local subsidiaries in the United States, Mexico, Chile and Brazil, all wholly owned, and exports made up 60.93% of orthopedic implant sales in 2025.

In competition, global spinal implants have been dominated by multinational players such as Medtronic and Stryker, which together hold more than 60% of the market. Medyssey is working to gain share from imported products through FDA clearance and expanded supply contracts. Production is handled in-house at its Jecheon plant in Chungcheongbuk-do.

03

Recent trends

The annual financial statements for the 23rd fiscal term, covering January to December 2025, were approved at the shareholders meeting on March 24, 2026. Based on the disclosure, 2025 consolidated revenue was KRW 28.309 billion, operating profit KRW 3.953 billion, and net income KRW 3.328 billion.

On a standalone basis, revenue was KRW 27.689 billion, operating profit KRW 4.053 billion, and net income KRW 3.795 billion. Consolidated revenue for 2024 was KRW 25.5 billion and operating profit KRW 3.2 billion.

According to a corporate data aggregate, 2024 consolidated revenue fell 4% year on year while operating profit rose 45.2%. The company said global sales for 2024 grew about 10% to roughly 10.63 million dollars, with lower selling and manufacturing costs contributing to profitability.

For fiscal 2020, revenue was KRW 18.76 billion with a net loss of about KRW 100 million, which shows how volatile earnings have been. As of 02:10 KST on November 11, 2026, the share price was KRW 11,470, down 4.42% from the prior close, with trading value of KRW 24,598,090.

The 52-week high and low, as aggregated at the time of lookup, were KRW 13,400 and KRW 6,800. Foreign ownership stood at 1.06%, and the free float ratio at 33.91%.

04

Outlook

Overseas business is the key variable for future results. By region, 2023 sales were led by the United States at 18.17%, Latin America at 13.47% and Asia at 14.77%, and roughly half of revenue comes from abroad.

After closing its Chinese and Brazilian subsidiaries, the company said it is preparing a partnership-led sales approach. Whether this approach takes hold, and whether overseas profit swings narrow, is the next checkpoint.

On products, the company has cited endoscopic spinal implants and consumables such as bone substitutes and hemostats as areas for expansion. It also said it is adding 3D printing equipment and hiring design and production staff.

On the KOSDAQ transfer, the company told investors in an October 2024 briefing that momentum would build around the end of 2025. A Korean IR research center expected that a transfer listing would remove a valuation discount. Because this timetable reflects a 2024 outlook, whether later disclosures update it is the next checkpoint.

05

Bull factors

FDA-backed overseas push in a concentrated market

Global spinal implants have been dominated by a handful of multinationals holding more than 60% of the market. Reports say Medyssey has secured FDA clearance and is expanding supply contracts to gain share from imported products.

With overseas sales near half of revenue, rising demand abroad could translate directly into top-line growth. Its 3D-printed patient-specific implants grew 29% to KRW 760 million in 2024 and are cited as a new growth engine.

Operating profit gains from cost efficiency

Consolidated operating profit for 2025 was KRW 3.953 billion, above the KRW 3.2 billion of 2024, and the rise in operating profit outpaced revenue growth. The company attributed its 2024 profitability improvement to lower selling, general and administrative costs and manufacturing costs.

Consolidated net income for 2025 of KRW 3.328 billion kept the company in the black. Whether this cost structure holds will determine the trend in operating margin.

KOSDAQ transfer plans and parent support

The company says it is preparing a transfer listing to KOSDAQ and that its earnings pose no obstacle to it. A Korean IR research center said it expected the move to remove a valuation discount. Reports describe Dong-Wha Pharm as providing broad support to Medyssey as its largest shareholder. The timing is uncertain because the listing timetable reflects a 2024 outlook.

06

Bear factors

Weak overseas units and impairment history

The Chinese joint venture was suspended and closed after persistent sales weakness, and Medyssey wrote off about KRW 1.7 billion of its carrying value in full. The Brazilian unit posted losses in most years since its 2016 founding, and it even recorded negative revenue in 2023.

Analysts cited this overseas weakness as one reason for lower profitability in recent years. Whether results stabilize after the restructuring can be tracked through quarterly disclosures.

Earnings volatility and finance cost exposure

Consolidated net income fell from KRW 5.1 billion in 2021 to KRW 2.4 billion in 2023, a decline of more than half. In fiscal 2020, finance costs surged to KRW 2.4 billion as foreign exchange losses and derivative valuation losses were recognized, leading to a net loss.

With a high overseas sales mix, currency swings can move earnings. Operating profit has improved, but net income can still vary widely depending on financing and currency items.

Thin KONEX liquidity and limited free float

On November 11, 2026, trading value was about KRW 24.6 million against a market capitalization of KRW 42.7 billion, which indicates thin trading. Foreign ownership stands at 1.06%, and the free float ratio is 33.91%. The large stake held by the controlling shareholder limits the shares available for trading.

Until a KOSDAQ transfer, price formation and trading conditions remain shaped by the structure of the KONEX market.

07

Risk factors

Macro

About half of revenue comes from overseas subsidiaries and export contracts in the United States, Latin America and Asia. Movements in the won-dollar rate and local currencies can affect translated sales and generate foreign exchange and derivative valuation gains or losses.

In fiscal 2020, foreign currency translation and derivative valuation losses pushed finance costs sharply higher. Global medical device demand and overseas hospital spending conditions are indirect variables as well.

Policy & reimbursement

Roughly 80% of domestic sales come from reimbursed products, so changes to reimbursement criteria and fee schedules directly affect demand. Abroad, country-by-country product certification governs how fast sales can expand, and completed certifications add to the count of export markets.

FDA clearance and expanded supply contracts underpin share gains, but the scope of approval varies by product. Shifts in the regulatory environment can affect the product lineup and pricing structure directly.

Liquidity & listing timing

Because the stock trades on KONEX, trading value and institutional and foreign participation are limited, so trading conditions differ from those of KOSDAQ-listed peers. The KOSDAQ transfer timetable reflects a 2024 outlook and could be delayed or change in terms.

The high stake held by Dong-Wha Pharm means any change in capital structure would interact with the supply of tradable shares. These factors shape market participation separately from operating indicators.

08

Overall view

Medyssey's consolidated revenue and operating profit for 2025 rose from the prior year, and the company operates an export-oriented model with roughly half of sales coming from abroad.

Pursuing share gains in a concentrated spinal implant market through FDA clearance and expanded supply contracts is cited as a bull factor.

On the other side, the impairment and closure of the Chinese and Brazilian units, the decline in net income since 2021, and the surge in finance costs in fiscal 2020 weigh on earnings stability. Limited trading value and foreign ownership on KONEX, along with a high controlling stake, also constrain the free float.

The planned KOSDAQ transfer could change the market structure, but its timetable reflects a 2024 outlook. The indicators to track are the overseas sales mix, operating margin, profit by overseas unit, and disclosures related to the transfer listing.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 11 more articles and sources
  1. news.nate.com
  2. pharm.edaily.co.kr
  3. comp.wisereport.co.kr
  4. comp.wisereport.co.kr
  5. press9.kr
  6. newstomato.com
  7. m.dailypharm.com
  8. pharm.edaily.co.kr
  9. pharm.edaily.co.kr
  10. medicopharma.co.kr
  11. itooza.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis